GlassScriptPhysician profile
David A Deloera
NPI 1881171536
$1,615.82
in general payments reported to CMS, 2019-2025
12 companies · $522 in 2025
The $522 reported for 2025 was less than what a typical Nephrology (Registered Nurse) provider received nationally (typical 2025 total: $522).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $380 · 2022: $361 · 2023: $286 · 2024: $67.85 · 2025: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $875.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $234.07 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $200.47 | 2021-2023 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $192.40 | 2022-2023 | Farxiga |
| Ardelyx, INC. | $191.68 | 2024-2025 | Xphozah 30 Mg |
| Vifor Pharma, INC. | $185.15 | 2022 | |
| Edwards Lifesciences Corporation | $148.07 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $131.51 | 2021-2023 | |
| Travere Therapeutics, INC. | $127.68 | 2025 | Filspari |
| Amgen INC. | $122.19 | 2025 | Krystexxa |
| Fresenius USA Marketing, INC. | $52.83 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $16.46 | 2021 | |
| Mallinckrodt Hospital Products INC. | $13.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Deloera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.